.
2616 financial statements
* Numbers in millions
Year |
2019 | 2020 | TTM |
|---|---|---|---|
Capitalization * |
9 291 | 10 941 | 5 617 |
EV * |
8 169 | 8 001 | 8 001 |
Stock price ¤ |
10.72 | 10.46 | 5.37 |
Number of shares * |
867 | 1 046 | 1 046 |
EPS |
-2,66 | -1,17 | -1,17 |
Revenue * |
0 | 1 039 | 1 039 |
Net income * |
-2 308 | -1 221 | -1 221 |
Operating profit * |
-1 738 | -1 064 | -1 064 |
Total liabilities * |
469 | 808 | 808 |
Net debt * |
-1 122 | -2 941 | -2 941 |
Total assets * |
2 951 | 3 763 | 3 763 |
Equity * |
2 482 | 2 954 | 2 954 |
Cash and investments * |
2 743 | 3 394 | 3 394 |
Over the past 10 years, the maximum capitalization of CStone Pharmaceuticals is 10 941, the minimum is 9 291. Maximum net income 0, Minimum net income -2 308. The maximum price of 2616 shares is 10.72, the minimum price is 10.46.
.
2616 valuation
Year |
2019 | 2020 | TTM |
|---|---|---|---|
P/E |
-4,02 | -8,96 | -4,60 |
P/B |
3,74 | 3,70 | 1,90 |
P/S |
0,00 | 10,53 | 5,41 |
E/P |
-25% | -11% | -22% |
P/FCF |
-8,51 | -18,88 | -9,69 |
.
2616 profitability
Year |
2019 | 2020 | TTM |
|---|---|---|---|
ROE |
-93% | -41% | |
ROA |
-78% | -33% | |
ROIC |
-70% | -35% |